48,706
edits
(→IHC) |
|||
(2 intermediate revisions by the same user not shown) | |||
Line 8: | Line 8: | ||
Staging of bladder cancer is dealt with in the ''[[bladder cancer staging]]'' article. | Staging of bladder cancer is dealt with in the ''[[bladder cancer staging]]'' article. | ||
'''''Muscle invasive bladder cancer''''' redirects to this article and refers to invasion of the ''muscularis propria''. | '''''Muscle invasive bladder cancer''''' redirects to this article and refers to invasion of the ''muscularis propria''. | ||
''Bladder muscularis propria invasion'' and ''urinary bladder muscularis propria invasion'' redirect to this article. | |||
==General== | ==General== | ||
Line 69: | Line 71: | ||
Image: Muscle invasive urothelial carcinoma -- high mag.jpg | MIUC - high mag. | Image: Muscle invasive urothelial carcinoma -- high mag.jpg | MIUC - high mag. | ||
</gallery> | </gallery> | ||
==IHC== | |||
''Smoothelin'' [[immunostain]]:<ref name=pmid18936687>{{Cite journal | last1 = Paner | first1 = GP. | last2 = Shen | first2 = SS. | last3 = Lapetino | first3 = S. | last4 = Venkataraman | first4 = G. | last5 = Barkan | first5 = GA. | last6 = Quek | first6 = ML. | last7 = Ro | first7 = JY. | last8 = Amin | first8 = MB. | title = Diagnostic utility of antibody to smoothelin in the distinction of muscularis propria from muscularis mucosae of the urinary bladder: a potential ancillary tool in the pathologic staging of invasive urothelial carcinoma. | journal = Am J Surg Pathol | volume = 33 | issue = 1 | pages = 91-8 | month = Jan | year = 2009 | doi = 10.1097/PAS.0b013e3181804727 | PMID = 18936687 }}</ref> | |||
*Muscularis propria - usu. strong. † | |||
*Muscularis mucosae - negative/weak. † | |||
Note: | |||
*† Overlap between the patterns is described;<ref name=pmid20154589>{{Cite journal | last1 = Miyamoto | first1 = H. | last2 = Sharma | first2 = RB. | last3 = Illei | first3 = PB. | last4 = Epstein | first4 = JI. | title = Pitfalls in the use of smoothelin to identify muscularis propria invasion by urothelial carcinoma. | journal = Am J Surg Pathol | volume = 34 | issue = 3 | pages = 418-22 | month = Mar | year = 2010 | doi = 10.1097/PAS.0b013e3181ce5066 | PMID = 20154589 }}</ref> this limits the utility of the immunostain. | |||
**Immunostain '''not''' used in many practice environments. | |||
==Sign out== | ==Sign out== |
edits